help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lobaccaro, J.-M.
Right arrow Articles by Sultan, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lobaccaro, J.-M.
Right arrow Articles by Sultan, C.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*12-O-TETRADECANOYLPHORBOL-13-ACETATE
*Genetics Home Reference
Endocrinology Vol. 140, No. 1 350-357
Copyright © 1999 by The Endocrine Society


ARTICLES

Transcriptional Interferences between Normal or Mutant Androgen Receptors and the Activator Protein 1—Dissection of the Androgen Receptor Functional Domains1

Jean-Marc Lobaccaro2, Nicolas Poujol, Béatrice Térouanne, Virginie Georget, Stéphane Fabre, Serge Lumbroso and Charles Sultan

Institut National de la Santé et de la Recherche Médicale (J.-M.L., N.P., B.T., V.G., S.L,. C.S)., INSERM U439, Pathologie Moléculaire des Récepteurs Nucléaires, 34090 Montpellier, France; Unité Biochimie Endocrinienne du Développement et de la Reproduction, Hôpital Lapeyronie (N.P., S.L., C.S.), 34295 Montpellier, France; Physiologie Comparée et Endocrinologie (S.F.), CNRS-ERS63, Les Cézeaux, 63177 Aubières, France; Unité Endocrinologie Pédiatrique (C.S.), Hôpital A. de Villeneuve, 34295 Montpellier, France

Address all correspondence and requests for reprints to: Prof. Charles Sultan, INSERM Unité 439, 70 rue de Navacelles, 34090 Montpellier, France. E-mail: chsultan{at}u439.montp.inserm.fr

We investigated the interferences of the normal or mutated androgen receptor with the activator protein-1 (AP-1) by assessing their effects on transcriptional activity in CV-1 cells. A luciferase reporter gene was constructed downstream from either a promoter for the mouse vas deferens protein, or a trimerized 12-O-tetradecanoyl phorbol-13-acetate-response element site whose transcriptions are activated by androgen and 12-O-tetradecanoyl phorbol-13-acetate, a potent AP-1 activator. The blockade of dephosphorylation by protein phosphatases identifies the protein phosphatases that modulate the AP-1/androgen receptor cross-talk. Using engineered or naturally occurring androgen receptor mutants that are responsible for complete or partial androgen insensitivity syndromes, we defined the subregions involved in the cross-talk of the androgen receptor with the AP-1 factors. First, it appears that the 188 first amino acids of the N-terminal domain of the androgen receptor are necessary to obtain a full transrepression. Second, a functional and intact ligand binding domain is critical for the modulation of androgen/AP-1 pathway interactions. Third, normal DNA binding capacity of the androgen receptor is not required. Two mutants at positions 568 and 581 of the DNA binding domain demonstrate that the transactivation and transrepression functions of the androgen receptor can be dissociated. Collectively, these data indicate that several segments of the androgen receptor are involved in cross-talk with the AP-1 pathway. Mutations within the DNA binding domain of the androgen receptor highly impair these interferences.




This article has been cited by other articles:


Home page
Endocr. Rev.Home page
H. V. Heemers and D. J. Tindall
Androgen Receptor (AR) Coregulators: A Diversity of Functions Converging on and Regulating the AR Transcriptional Complex
Endocr. Rev., December 1, 2007; 28(7): 778 - 808.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
K. L Golden, J. D Marsh, Y. Jiang, and J. Moulden
Acute actions of testosterone on contractile function of isolated rat ventricular myocytes
Eur. J. Endocrinol., March 1, 2005; 152(3): 479 - 483.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Q. Wang, T. S. Udayakumar, T. S. Vasaitis, A. M. Brodie, and J. D. Fondell
Mechanistic Relationship between Androgen Receptor Polyglutamine Tract Truncation and Androgen-dependent Transcriptional Hyperactivity in Prostate Cancer Cells
J. Biol. Chem., April 23, 2004; 279(17): 17319 - 17328.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. V. Nantermet, J. Xu, Y. Yu, P. Hodor, D. Holder, S. Adamski, M. A. Gentile, D. B. Kimmel, S.-i. Harada, D. Gerhold, et al.
Identification of Genetic Pathways Activated by the Androgen Receptor during the Induction of Proliferation in the Ventral Prostate Gland
J. Biol. Chem., January 9, 2004; 279(2): 1310 - 1322.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
K. L. Golden, J. D. Marsh, Y. Jiang, T. Brown, and J. Moulden
Gonadectomy of adult male rats reduces contractility of isolated cardiac myocytes
Am J Physiol Endocrinol Metab, September 1, 2003; 285(3): E449 - E453.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G.-Z. Liu, H. Wang, and Z. Wang
Identification of a Highly Conserved Domain in the Androgen Receptor That Suppresses the DNA-binding Domain-DNA Interactions
J. Biol. Chem., April 18, 2003; 278(17): 14956 - 14960.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
B. Terouanne, P. Nirde, F. Rabenoelina, W. Bourguet, C. Sultan, and G. Auzou
Mutation of the Androgen Receptor at Amino Acid 708 (Glyright-arrowAla) Abolishes Partial Agonist Activity of Steroidal Antiandrogens
Mol. Pharmacol., April 1, 2003; 63(4): 791 - 798.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
N. Poujol, S. Lumbroso, B. Terouanne, J.-M. A. Lobaccaro, W. Bourguet, and C. Sultan
Pathophysiology of Androgen Insensitivity Syndromes: Molecular and Structural Approaches of Natural and Engineered Androgen Receptor Mutations at Amino Acid 743
J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5793 - 5800.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
V. S. Wilson, K. Bobseine, C. R. Lambright, and L. E. Gray Jr.
A Novel Cell Line, MDA-kb2, That Stably Expresses an Androgen- and Glucocorticoid-Responsive Reporter for the Detection of Hormone Receptor Agonists and Antagonists
Toxicol. Sci., March 1, 2002; 66(1): 69 - 81.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
B. H. Chung, S. H. Mitchell, J.-S. Zhang, and C. Y. F. Young
Effects of docosahexaenoic acid and eicosapentaenoic acid on androgen-mediated cell growth and gene expression in LNCaP prostate cancer cells
Carcinogenesis, August 1, 2001; 22(8): 1201 - 1206.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P.-M. Holterhus, G. H. G. Sinnecker, and O. Hiort
Phenotypic Diversity and Testosterone-Induced Normalization of Mutant L712F Androgen Receptor Function in a Kindred with Androgen Insensitivity
J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3245 - 3250.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
Q. Wang, J. Lu, and E. L. Yong
Ligand- and Coactivator-mediated Transactivation Function (AF2) of the Androgen Receptor Ligand-binding Domain Is Inhibited by the Cognate Hinge Region
J. Biol. Chem., March 2, 2001; 276(10): 7493 - 7499.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1999 by The Endocrine Society